A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
NCT ID: NCT00772486
Last Updated: 2021-09-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
13 participants
Study Classification
INTERVENTIONAL
Study Start Date
2008-09-30
Study Completion Date
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is a Phase 1b open label, non-randomized, single institution clinical trial that is designed to evaluate the safety and tolerability of three repeat infusions of ISF35 followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) in subjects with refractory, resistant, and/or 17p- CLL.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
NCT00779883
Chronic Lymphocytic Leukemia
COMPLETED
PHASE1
Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT00850057
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
COMPLETED
PHASE1
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT00849524
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
TERMINATED
PHASE2
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
NCT02158091
Chronic Lymphocytic Leukemia
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Chronic Lymphocytic Leukemia
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ISF35 has already been used in two Phase I clinical trials. The trials demonstrated that ISF35 treatment is well tolerated and patients did not experience any significant or unexpected adverse events. Patients reported flu-like symptoms from ISF35, which disappeared within one to three days.
The trials also showed that ISF35 stimulates the immune system to act against CLL cells and sensitize leukemic cells to subsequent treatment. Repeat infusions of ISF35 administered as a single agent to subjects with CLL resulted in durable reductions in circulating and lymph-node bound leukemic cells. Furthermore, CLL patients with 17p deletion responded to standard courses of FCR after receiving ISF35 and achieved durable remissions.
ISF35 is an abbreviation for Immune Stimulatory Factor 35, an offspring of technology discovered by Dr. Thomas J. Kipps, MD, PhD, Professor, Department of Medicine and Deputy Director for Research,UCSD Moores Cancer Center.
The trials also showed that ISF35 stimulates the immune system to act against CLL cells and sensitize leukemic cells to subsequent treatment. Repeat infusions of ISF35 administered as a single agent to subjects with CLL resulted in durable reductions in circulating and lymph-node bound leukemic cells. Furthermore, CLL patients with 17p deletion responded to standard courses of FCR after receiving ISF35 and achieved durable remissions.
ISF35 is an abbreviation for Immune Stimulatory Factor 35, an offspring of technology discovered by Dr. Thomas J. Kipps, MD, PhD, Professor, Department of Medicine and Deputy Director for Research,UCSD Moores Cancer Center.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Chronic Lymphocytic Leukemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: ISF35 and FCR
ISF35 and FCR
Group Type
EXPERIMENTAL
ISF35
Intervention Type
BIOLOGICAL
Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ISF35
Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Ad-ISF35
AdISF35
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects must have a diagnosis of B cell CLL including:
* Lymphocytosis of monoclonal B-cells co-expressing ≥ one B-cell marker (CD19, CD20, or CD23) and CD5 in peripheral blood or lymph node AND
* Bone marrow with ≥ 30% mononuclear cells having the CLL/SLL phenotype
2. Measurable disease, and at least one of the IWCLL 2008 Guidelines "Indications for Treatment" as follows:
* Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia.
* Massive (i.e., \>6 cm below the left costal margin) or progressive or asymptomatic splenomegaly.
* Massive nodes (i.e., \>10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
* Progressive lymphocytosis with an increase of \>50% over a 2-month period, or lymphocyte doubling time (LDT) of less than 6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts (ALC) obtained at intervals of two weeks over an observation period of 2-3 months; patients with initial blood lymphocyte counts of less than 30,000 per microliter may require a longer observation period to determine the LDT. Also, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g, infections) should be excluded.
* Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids or other standard therapy.
* A minimum of any one of the following disease-related symptoms must be present:
* Unintentional weight loss ≥10% within the previous 6 months.
* Significant fatigue (i.e., ECOG PS 2 or worse; cannot work or unable to perform usual activities).
* Fevers of greater than 100.5 degrees F or 38.0 degrees C for 2 or more weeks without other evidence of infection.
* Night sweats for more than 1 month without evidence of infection. Hypogammaglobulinemia or monoclonal or oligoclonal paraproteinemia does not by itself constitute a basis to initiate treatment.
3. Subjects must have CLL that is documented to be resistant or refractory to standard chemotherapy regimens containing alkylating agents and/or purine analogues. Chemotherapy refractory or resistant is defined as the following:
* CLL progression during treatment (2 cycles) with chemotherapy; OR
* Failure to achieve a PR or CR after at least 2 cycles of chemotherapy; OR
* No response to treatment or stable disease after at least 2 cycles of chemotherapy; OR
* Disease progression within 6 months of treatment with chemotherapy; OR
* CLL with cytogenetic changes documenting the loss of the short arm of chromosome 17 (17p-) associated with the loss of p53.
4. Subjects must be age 18 years or older
5. For men and women of child-bearing potential, use of effective barrier contraceptive methods during the study and for one month following treatment
6. Subjects must have ECOG performance scale of ≤ 2
7. Subjects must have adequate hematologic, renal, hepatic, and coagulation function defined as:
• Adequate hematologic function:
i) Platelet count ≥ 50,000/µL; AND
ii) Hemoglobin ≥ 10 g/dL (may be supported by erythropoietin or transfusion); AND
• Adequate renal function:
i) Calculated creatinine clearance ≥ 30 mL/min/1.73 m\^2; OR
ii) Serum creatinine ≤ 2 times upper limit of normal; AND
• Adequate hepatic function:
i) Total bilirubin ≤ 2.5 times upper limit of normal; AND
ii) ALT ≤ 2.5 times upper limit of normal; AND
• Adequate coagulation tests:
i) Prothrombin time international normalized ratio (INR) ≤ 1.5; AND
ii) Partial thromboplastin time ≤ 1.5 times upper limit of normal
8. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments
* Lymphocytosis of monoclonal B-cells co-expressing ≥ one B-cell marker (CD19, CD20, or CD23) and CD5 in peripheral blood or lymph node AND
* Bone marrow with ≥ 30% mononuclear cells having the CLL/SLL phenotype
2. Measurable disease, and at least one of the IWCLL 2008 Guidelines "Indications for Treatment" as follows:
* Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia.
* Massive (i.e., \>6 cm below the left costal margin) or progressive or asymptomatic splenomegaly.
* Massive nodes (i.e., \>10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
* Progressive lymphocytosis with an increase of \>50% over a 2-month period, or lymphocyte doubling time (LDT) of less than 6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts (ALC) obtained at intervals of two weeks over an observation period of 2-3 months; patients with initial blood lymphocyte counts of less than 30,000 per microliter may require a longer observation period to determine the LDT. Also, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g, infections) should be excluded.
* Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids or other standard therapy.
* A minimum of any one of the following disease-related symptoms must be present:
* Unintentional weight loss ≥10% within the previous 6 months.
* Significant fatigue (i.e., ECOG PS 2 or worse; cannot work or unable to perform usual activities).
* Fevers of greater than 100.5 degrees F or 38.0 degrees C for 2 or more weeks without other evidence of infection.
* Night sweats for more than 1 month without evidence of infection. Hypogammaglobulinemia or monoclonal or oligoclonal paraproteinemia does not by itself constitute a basis to initiate treatment.
3. Subjects must have CLL that is documented to be resistant or refractory to standard chemotherapy regimens containing alkylating agents and/or purine analogues. Chemotherapy refractory or resistant is defined as the following:
* CLL progression during treatment (2 cycles) with chemotherapy; OR
* Failure to achieve a PR or CR after at least 2 cycles of chemotherapy; OR
* No response to treatment or stable disease after at least 2 cycles of chemotherapy; OR
* Disease progression within 6 months of treatment with chemotherapy; OR
* CLL with cytogenetic changes documenting the loss of the short arm of chromosome 17 (17p-) associated with the loss of p53.
4. Subjects must be age 18 years or older
5. For men and women of child-bearing potential, use of effective barrier contraceptive methods during the study and for one month following treatment
6. Subjects must have ECOG performance scale of ≤ 2
7. Subjects must have adequate hematologic, renal, hepatic, and coagulation function defined as:
• Adequate hematologic function:
i) Platelet count ≥ 50,000/µL; AND
ii) Hemoglobin ≥ 10 g/dL (may be supported by erythropoietin or transfusion); AND
• Adequate renal function:
i) Calculated creatinine clearance ≥ 30 mL/min/1.73 m\^2; OR
ii) Serum creatinine ≤ 2 times upper limit of normal; AND
• Adequate hepatic function:
i) Total bilirubin ≤ 2.5 times upper limit of normal; AND
ii) ALT ≤ 2.5 times upper limit of normal; AND
• Adequate coagulation tests:
i) Prothrombin time international normalized ratio (INR) ≤ 1.5; AND
ii) Partial thromboplastin time ≤ 1.5 times upper limit of normal
8. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments
Exclusion Criteria
1. Presence of \> 55% prolymphocytes or Richter's transformation
2. Chemotherapy (e.g., purine analogues, alkylating agents, or corticosteroids), antibody therapy, immunotherapy, radiation therapy, or participation in any investigational drug treatment within 4 weeks of enrollment into protocol or at any time during the study
3. Ongoing toxicity from prior anti-neoplastic therapy
4. Untreated autoimmune hemolytic anemia or immune thrombocytopenia
5. Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis
6. Positive serologies for HIV1,2 or HTLV I,II
7. CMV disease with positive DNA PCR
8. Syphilis with positive VDRL
9. Acute Hepatitis A and C with positive serologies, and Hepatitis B, acutely or chronically infected based on CDC criteria
10. Any illness or condition that in opinion of the investigator may affect safety of treatment or evaluation of any study's endpoints
2. Chemotherapy (e.g., purine analogues, alkylating agents, or corticosteroids), antibody therapy, immunotherapy, radiation therapy, or participation in any investigational drug treatment within 4 weeks of enrollment into protocol or at any time during the study
3. Ongoing toxicity from prior anti-neoplastic therapy
4. Untreated autoimmune hemolytic anemia or immune thrombocytopenia
5. Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis
6. Positive serologies for HIV1,2 or HTLV I,II
7. CMV disease with positive DNA PCR
8. Syphilis with positive VDRL
9. Acute Hepatitis A and C with positive serologies, and Hepatitis B, acutely or chronically infected based on CDC criteria
10. Any illness or condition that in opinion of the investigator may affect safety of treatment or evaluation of any study's endpoints
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Leukemia and Lymphoma Society
OTHER
Sponsor Role
collaborator
University of California, San Diego
OTHER
Sponsor Role
collaborator
Memgen, LLC
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Januario Castro, MD
Role: PRINCIPAL_INVESTIGATOR
Assistant Clinical Professor in the Blood and Marrow Transplantation Division
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Diego Moores Cancer Center
San Diego, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4079-88. doi: 10.1200/JCO.2005.12.051. Epub 2005 Mar 14.
Reference Type
BACKGROUND
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23.
Reference Type
BACKGROUND
Rai KR. Characteristics and Management of Chronic Lymphocytic Leukemia. Advances in Oncology. 1996;9 No.1:17-20.
Reference Type
BACKGROUND
Kalil N, Cheson BD. Chronic lymphocytic leukemia. Oncologist. 1999;4(5):352-69.
Reference Type
BACKGROUND
Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2002:193-213. doi: 10.1182/asheducation-2002.1.193.
Reference Type
BACKGROUND
Bosch F, Montserrat E. Refining prognostic factors in chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2002 Dec;6(4):335-49; discussion 449-50. doi: 10.1046/j.1468-0734.2002.00302.x. No abstract available.
Reference Type
BACKGROUND
Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol. 2000 Oct;27(5):587-97.
Reference Type
BACKGROUND
Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res. 2004 May;28(5):429-42. doi: 10.1016/j.leukres.2003.08.017.
Reference Type
BACKGROUND
Nabhan C, Dyer MJ, Rosen ST. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology (Williston Park). 2003 Feb;17(2):253-62; discussion 264, 267, passim.
Reference Type
BACKGROUND
Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2004:163-83. doi: 10.1182/asheducation-2004.1.163.
Reference Type
BACKGROUND
Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995 Oct 19;333(16):1052-7. doi: 10.1056/NEJM199510193331606. No abstract available.
Reference Type
BACKGROUND
Ghia P, Caligaris-Cappio F. The origin of B-cell chronic lymphocytic leukemia. Semin Oncol. 2006 Apr;33(2):150-6. doi: 10.1053/j.seminoncol.2006.01.009.
Reference Type
BACKGROUND
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005 Feb 24;352(8):804-15. doi: 10.1056/NEJMra041720. No abstract available.
Reference Type
BACKGROUND
Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Jan;43(1):149-51. doi: 10.1080/10428190210178.
Reference Type
BACKGROUND
Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988 Nov;29(3):152-63. doi: 10.1002/ajh.2830290307.
Reference Type
BACKGROUND
Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol. 2003 Aug;30(4):483-92. doi: 10.1016/s0093-7754(03)00239-2.
Reference Type
BACKGROUND
O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15;19(8):2165-70. doi: 10.1200/JCO.2001.19.8.2165.
Reference Type
BACKGROUND
Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005 Jan 1;105(1):49-53. doi: 10.1182/blood-2004-03-0796. Epub 2004 May 11.
Reference Type
BACKGROUND
Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070-8. doi: 10.1200/JCO.2005.12.516. Epub 2005 Mar 14.
Reference Type
BACKGROUND
Kipps TJ. Chronic lymphocytic leukemia and related diseases. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Hematology (ed 6). New York: McGraw-Hill, Inc.; 2001:1163-1194.
Reference Type
BACKGROUND
Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000 Nov 1;96(9):2917-24.
Reference Type
BACKGROUND
Dicker F, Kater AP, Fukuda T, Kipps TJ. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood. 2005 Apr 15;105(8):3193-8. doi: 10.1182/blood-2003-10-3684. Epub 2004 Aug 31.
Reference Type
BACKGROUND
Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3854-9. doi: 10.1073/pnas.022604399. Epub 2002 Mar 12.
Reference Type
BACKGROUND
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 28;343(26):1910-6. doi: 10.1056/NEJM200012283432602.
Reference Type
BACKGROUND
Cantwell MJ, Sharma S, Friedmann T, Kipps TJ. Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood. 1996 Dec 15;88(12):4676-83.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.leukemia-lymphoma.org/all_news_detail?item_id=520809&cat_id=140
LLS, Memgen Collaborate on CLL Clinical Trial
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLL-35-104
Identifier Type: -
Identifier Source: org_study_id
NCT00796016
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT00391066
TERMINATED
PHASE2
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT00801060
TERMINATED
PHASE2
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
NCT01564784
COMPLETED
PHASE3
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02117336
SUSPENDED
PHASE1
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT00103558
COMPLETED
PHASE1/PHASE2
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
NCT00412243
COMPLETED
PHASE1/PHASE2
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
NCT00281918
COMPLETED
PHASE3
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
NCT01363297
COMPLETED
PHASE2
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT01082939
COMPLETED
PHASE2
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
NCT01925131
COMPLETED
PHASE1
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
NCT02251548
ACTIVE_NOT_RECRUITING
PHASE2
CFAR Study in Patients With Chronic Lymphocytic Leukemia
NCT00525603
COMPLETED
PHASE2
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00536341
COMPLETED
PHASE1/PHASE2
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
NCT05944978
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00101296
COMPLETED
PHASE1
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
NCT00293410
COMPLETED
PHASE1
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
NCT03106428
COMPLETED
PHASE1
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04434196
COMPLETED
PHASE1
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
NCT04155710
COMPLETED
PHASE1
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT04956042
TERMINATED
PHASE1/PHASE2
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable
NCT00924443
COMPLETED
PHASE2
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT04315324
RECRUITING
PHASE1/PHASE2
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01757639
COMPLETED
PHASE1